Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Parkinson’s Disease Market Growth Performance Trended Historically, And What Lies Ahead?

In recent times, there has been substantial growth in the size of the Parkinson’s disease market. The market, which is set to increase from $3.34 billion in 2024 to $3.62 billion in 2025, shows a compound annual growth rate (CAGR) of 8.2%. This growth in the past period is linked to various factors including enhanced research and development efforts, more government funding, a rise in personalized treatment approaches, an increase in support networks dedicated to Parkinson’s disease patients, and more utilized advanced rehabilitation therapies.

Expectations for the parkinson’s disease market forecast a robust growth in the upcoming years, with predictions of the market size to reach$4.94 billion by 2029″, exhibiting a compound annual growth rate (CAGR) of 8.1%. Factors contributing to the projected growth during this period include escalating awareness about symptoms of parkinson’s disease, proactive government initiatives, enhancement in healthcare expenditures, an increase in clinical trials specific to Parkinson’s disease, and the growing preference for gene therapies. Upcoming trends during the forecast period encompass advancements in technology, government contributions, and funding, the incorporation of artificial intelligence in diagnoses, innovative solutions, and tailor-made medicine.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21247&type=smp

Which Factors and External Forces Are Driving Demand in the Parkinson’s Disease Market?

The growing incidence of neurodegenerative disorders is anticipated to fuel the development of the Parkinson’s disease market. Neurodegenerative disorders encompass a set of conditions characterized by the gradual deterioration and loss of brain and nervous system neurons’ ability. The occurrence of such disorders is on the rise due to numerous factors, including an aging populace, genetic susceptibility, ecological impacts, enhanced diagnostic measures, and increased chronic health issues. Parkinson’s disease aids in the elucidation of neurodegenerative disorders by providing crucial insights into their fundamental mechanisms, potential treatment targets, and innovative therapeutic methods’ creation. For instance, as per the European Brain Council, a non-profit organization based in Belgium, over 600 neurological disorders and nearly 300 psychiatric conditions plague millions worldwide, including those with epilepsy which is estimated to be around 65 million. In Europe, 10.5 million individuals are estimated to have dementia, with the figure projected to rise to 18.7 million by 2050. Hence, the growing incidence of neurodegenerative disorders propels the expansion of the Parkinson’s disease market.

Which Segments in the Parkinson’s Disease Offer the Most Growth?

The parkinson’s diseasemarket covered in this report is segmented –

1) By Drug Class: Dopamine Agonists; Catechol-O-Methyltransferase Inhibitors; Monoamine Oxidase B Inhibitors; Anticholinergics; Carbidopa-Levodopa; Other Drug Classes

2) By Route Of Administration: Oral; Injectable; Intestinal infusion; Subcutaneous; Other Route Of Administrations

3) By Distribution Channel: Retail Pharmacies; Hospital Pharmacies; Online Pharmacies

4) By Patient Care Setting: Clinics; Hospitals

Subsegments:

1) By Dopamine Agonists: Ergot Derivatives; Non-Ergot Derivatives

2) By Catechol-O-Methyltransferase (COMT) Inhibitors: Entacapone; Tolcapone; Opicapone

3) By Monoamine Oxidase B (MAO-B) Inhibitors: Selegiline; Rasagiline; Safinamide

4) By Anticholinergics: Trihexyphenidyl; Benztropine; Procyclidine

5) By Carbidopa-Levodopa: Immediate-Release Formulation; Extended-Release Formulation; Inhaled And Intestinal Gel Formulations

6) By Other Drug Classes: Amantadine And Derivatives; Adenosine A2A Receptor Antagonists; Glutamate Antagonists

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=21247&type=smp

What Are the Fastest-Growing Geographies in the #Which Factors and External Forces Are Driving Demand in the Parkinson’s Disease Market?# Market?

North America was the largest region in the parkinson’s disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the parkinson’s disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Which Cutting-Edge Market Trends Are Expected to Drive theParkinson’s Disease Market’s Growth?

Major firms working within the parkinson’s disease sphere are heavily investing in the creation of innovative solutions, such as levodopa-infused therapy, with the aim to boost motor function and deliver consistent management of symptoms for individuals with advanced parkinson’s disease. This kind of therapeutic approach employs levodopa, a drug that transforms into dopamine in the brain, to boost motor capabilities and suppress the symptoms of Parkinson’s disease. For instance, in October 2024, AbbVie Inc., a biopharmaceutical business based in the US, got the green light from the US Food and Drug Administration (FDA) for their combination therapy VYALEV, which includes levodopa and carbidopa, engineered specifically for the treatment of Parkinson’s disease. This therapy has been designed to enhance the effectiveness of levodopa by preventing its breakdown before it arrives in the brain, effectively increasing dopamine levels. This prescription medication successfully manages motor symptoms of Parkinson’s, such as tremors, stiffness, and bradykinesia, therefore improving the patient’s daily functioning activities. It is hailed as a crucial treatment option for those Parkinson’s patients experiencing motor fluctuation.

View the full report here:

https://www.thebusinessresearchcompany.com/report/parkinsons-disease-global-market-report

What Are the Key Elements That Define the Parkinson’s Disease Market?

Parkinson’s disease is a progressive neurological disorder that affects movement due to the loss of dopamine-producing brain cells. It primarily causes tremors, muscle stiffness, slowed movement, and balance difficulties. Treatment often involves medications such as levodopa to alleviate symptoms, complemented by physical therapy and, in certain cases, surgical interventions such as deep brain stimulation.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21247

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model